A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.

doi:10.1007/s11523-021-00859-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.

Targeted oncology - 1 Jan 2022

Tu Hai-Yan, Feng Jifeng, Shi Meiqi, Zhao Jun, Wang Yuyan, Chang Jianhua, Wang Jialei, Cheng Ying, Zhu Jing, Tan Eng-Huat, Li Kai, Zhang Yiping, Lee Victor, Yang Cheng-Ta, Su Wu-Chou, Lam David Chi-Leung, Srinivasa B J, Rajappa Senthil, Ho Ching-Liang, Lam Kwok Chi, Hu Yi, Bondarde Shailesh Arjun, Liu Xiaoqing, Tian Yahui, Xue Zhiyi, Cseh Agnieszka, Huang Dennis Chin-Lun, Zhou Caicun, Wu Yi-Long

Abstract excerpt

BACKGROUND: Afatinib has been shown as a suitable option for the treatment of epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) in randomized controlled trials. However, patients treated in real-world clinical practice, including elderly patients, and those with brain metastases or poor Eastern Cooperative Oncology Group (ECOG) performance statuses, are often excluded...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged

Share to Brain Neoplasms

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 35020119
DOI: 10.1007/s11523-021-00859-6
PMCID: PMC8783858

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.PMID 35020119Read ↗

A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632.Semantic proximity Read ↗

Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.Semantic proximity Read ↗

Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.Semantic proximity Read ↗

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.Semantic proximity Read ↗

Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data.Semantic proximity Read ↗

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.Semantic proximity Read ↗

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.Semantic proximity Read ↗

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.Semantic proximity Read ↗

Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia.Semantic proximity Read ↗

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).Semantic proximity Read ↗

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings.Semantic proximity Read ↗

Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.